| ID | 1361 |
| Name of the vaccine | Minhai-HIB |
| Microbe | Bacteria |
| Disease name | Haemophilus influenzae type b (Hib) |
| Name of bacteria | Haemophilus influenzae |
| Type of vaccine | Conjugate |
| Nucleic acid content | DNA |
| Age | 2 to 5 years |
| Description of the vaccine | Haemophilus Influenzae type b conjugate vaccine, freeze-dried. |
| Name of the manufacturer | Beijing Minhai Biotechnology Co., Ltd |
| Name of the manufacturing country | China |
| Year of manufacture | 2016 |
| Clinical Phase status | Clinical - Phase 3 |
| Bacterial strain | Anaerobic gram-negative coccobacillus. |
| Efficacy | NA |
| Vaccine formulation | Suspension for injection |
| Dosage | Children 1 to 5 years: Single dose.
Children 6 to 11 months: Two doses, 1 month apart.
Infants 2 to 5 months: Three doses, 1 month apart. |
| Mechanism of action | NA |
| Route of administration | Intramuscular |
| Indications | NA |
| Export | NA |
| Approval | NA |
| Adjuvant | NA |
| Repurposing | NA |
| Side effects of vaccine | NA |
| Post vaccination | NA |
| Dose type | Both |
| Interspecies transfer | NA |
| PubMed identifier | NA |
| Clinical trial number | NCT02560272 |
| Reference | NA |
| Other name | NA |
| Additional Links | NA
|